FrontView REIT, Inc. FVR 深 沪
已收盘 04-02 16:00:00 美东时间
15.53
+0.080
+0.52%
华盛通- 最 高15.5393
- 今 开15.22
- 成交量 5.19万股
- 最 低 15.205
- 昨 收 15.45
- 总市值 3.47亿
- 52周最高 16.875
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 9.95
- 委 比 33.33%
- 总股本 2231.30万
- 历史最高 18.47
- 量 比 0.59
- 振 幅 2.16%
- 历史最低 9.75
- 每 手 1
- 风险率 1.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
B. Riley Securities Initiates Coverage On FrontView REIT with Buy Rating, Announces Price Target of $20.5
B. Riley Securities analyst John Massocca initiates coverage on FrontView REIT (NYSE:FVR) with a Buy rating and announces Price Target of $20.5.
03-19 18:31
FrontView REIT Q4 Earnings Summary & Key Takeaways
The Q4 earnings report for FrontView REIT (NYSE:FVR) was released on Tuesday, F...
02-25 05:08
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
Jones Trading Initiates Coverage On FrontView REIT with Buy Rating, Announces Price Target of $19
Jones Trading analyst Matthew Erdner initiates coverage on FrontView REIT (NYSE:FVR) with a Buy rating and announces Price Target of $19.
01-14 22:41
美股大行评级 | 潜在涨幅108.88%！TeraWulf获Keefe, Bruyette & Woods上调目标价至24美元，评级升至"跑赢大市"
今日重点评级关注：Keefe, Bruyette & Woods：上调TeraWulf Inc Ordinary Shares评级至"跑赢大市"，目标价从9.5美元升至24美元；B. Riley证券：维持万达生物制药"买入"评级，目标价从11美元升至14美元
01-02 15:10
Morgan Stanley Maintains Equal-Weight on FrontView REIT, Raises Price Target to $14
Morgan Stanley analyst Ronald Kamdem maintains FrontView REIT (NYSE:FVR) with a Equal-Weight and raises the price target from $13.5 to $14.
01-01 01:26
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
JP Morgan Maintains Neutral on FrontView REIT, Raises Price Target to $17
JP Morgan analyst Anthony Paolone maintains FrontView REIT (NYSE:FVR) with a Neutral and raises the price target from $15 to $17.
2025-12-08 23:55
